e-Drug3D

2146

ENSARTINIB

INN
ENSARTINIB

cas 1370651-20-9

CLASS

ANTINEOPLASTIC
KINASE INHIBITOR
TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)

ROUTE (list)

ORAL

ATC code

PK parameters

Tmax 3 HOUR
VD 1720 LITER
PPB 91.6 PERCENT
t1/2 30 HOUR

Target

TARGET ANAPLASTIC LYMPHOMA KINASE (ALK)
MET
ROS1

DrugCentral

Download SDF file

3-Pyridazinecarboxamide, 6-amino-5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-N-[4-[[(3R,5S)-3,5-dimethyl-1-piperazinyl]carbonyl]phenyl]- (ACI)

Formula:
C26H27Cl2FN6O3

Calculated chemical properties:

MW 561.44
NB_atoms 38
XLogP 4.72
PSA 114.913
NB_HD 4
NB_HA 9
fsp3 0.31
Lipinski(0=no;1=yes) 0

FDA
NDA 218171 (label) INN (ENSARTINIB HYDROCHLORIDE) ENSACOVE (XCOVERY) APPROVAL= AP YEAR= 2024 NEWMOLECULARENTITY